PamGene announces 7 poster presentations from its collaborators at the AACR meeting in San Diego, highlighting innovative applications of its kinase activity profiling platform

‘s-Hertogenbosch, the Netherlands, March 21, 2024 – PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, announced today the presentations of seven posters from its collaborators, which will be presented at the annual American Association for Cancer Research from April 5-10 in San Diego.

From April 5-10, PamGene will participate in the world’s largest annual event on innovations in cancer research, where it will meet with its existing academic and pharma biotech customer base. It also hopes to engage in discussions with researchers on new applications of its kinase activity profiling platform, as well as its diagnostics immunotherapy response prediction platform called IOpener®. Made possible by PamGene’s proprietary microarray-based kinase activity profiling of host immune cells, IOpener® can predict a patient’s response, before immunotherapy is started, from a simple blood draw. The IOpener® test platform aims to revolutionize the precision-medicine sector, enabling the widespread use of immunotherapy at any cancer stage.

“The research presented in these 7 posters underscores the value of measuring kinome activity using PamGene’s kinase-activity profiling platform, which can support basic-, translational- and clinical-research scientists in understanding the role of cell signaling and developing better tools to guide cancer treatment,” says John Groten, managing director of PamGene.

List of poster presentations:

  • April 7, afternoon: Section 21, board 11 (poster 514) – Salt-inducible kinase inhibitor OMX-0407 drives cell-cycle arrest in vitro and in vivo: An in-depth MoA analysis by phospho-proteomics. I.P. Maser et al. of iOmx Therapeutics AG, Munich, Germany (link)
  • April 7, afternoon: Section 44, board 21 (poster 1100) – Fascin-1 inhibitor decreases hepatoblastoma cells tumorigenicity via YAP 1. Dr. L. Dif et al. of Bordeaux Institute of Oncology, Bordeaux, France (link)
  • April 8, morning: Section 6, board 14 (poster 1443) – The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer. W.J. McDaid et al. of Cancer Research UK Manchester Institute, Manchester, United Kingdom (link)
  • April 9, morning: Section 23, board 29 (poster 4574) – Next generation nuclear export blocker KPT8602 synergizes with KRASG12D inhibitor MRTX1133 resulting in improved antitumor effects against pancreatic ductal adenocarcinoma. Dr. A. Aboukameel et al. of Barbara Ann Karmanos Cancer Institute, Detroit, MI, United States (link)
  • April 9, morning: Section 28, board 2 (poster 4682) – Membrane protein expression and activity following inhibition of B-cell receptor-initiated signaling by WBMP-4, a therapeutic antibody for leukemia/lymphoma. Dr. R.S. Welt et al. of Welt Bio-Molecular Pharmaceutical, Briarcliff Manor, NY, United States (link)
  • April 9, afternoon: Section 23, board 3 (poster 5827) – Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer. L.F. Ott et al. of University Medical Center Hamburg-Eppendorf, Hamburg, Germany (link)
  • April 9, afternoon: Section 27, board 9 (poster 5961) – NRF2-responsive kinases in esophageal squamous cell carcinoma. Dr. B. Subramaniyan of Cooper University Health Care, Camden, NJ, United States (link)

About IOpener® – A liquid biopsy immunotherapy guidance test
The IOpener® is a blood-based diagnostic test that supports immunotherapy guidance for melanoma and non-small cell lung cancer (NSCLC) patients. The test measures the kinase activity in peripheral blood mononuclear cells isolated from a single tube of blood from a patient to determine the likelihood of responding to immunotherapy. The test is based on ample experience with the technology for measuring and interpreting kinase activity to support academic and clinical research. The IOpener®-NSCLC and the IOpener®-melanoma are CE-IVD registered devices that are developed and manufactured in PamGene’s ISO 13485:2016 certified facility.

About PamGene
PamGene International B.V. has recently intensified its efforts to develop and commercialize a blood-based immunotherapy guidance test, the IOpener®, to improve patient outcomes. The company’s kinase-activity profiling technology and proprietary software algorithms support clinicians in their treatment decisions using the IOpener® assay. PamGene’s robust and unique peptide microarray technology for multiplex kinase-activity profiling is also used to provide dedicated assay services for patient stratification for clinical trials, biomarker discovery, and gaining mechanistic insights needed to understand human diseases. PamGene is headquartered in ‘s-Hertogenbosch, the Netherlands.

For more information, please contact Rinie van Beuningen, Vice President Business Development – – +31 (0) 73 615 80 80 –

IOpener® is a registered trademark in the U.S. and European community.

Related Posts